The Kirsten Ras (*KRAS*) proto-oncogene encodes for a guanosine triphosphate (GTP)/guanosine diphosphate binding protein downstream of the epidermal growth factor receptor (EGFR) in the RAS/RAF/MAPK pathway. Mutations in *KRAS* are evident in 30--40% of colorectal tumours ([@bib5]; [@bib34]; [@bib16]; [@bib38]; [@bib22]; [@bib14], [@bib15]; [@bib26]; [@bib33]; [@bib18]; [@bib20]; [@bib21]). Based on evidence that the benefits of adjuvant treatment with anti-EGFR chemotherapy for distant-stage metastatic colorectal cancer (CRC) are limited to patients with *KRAS*-wild-type disease ([@bib23]; [@bib7]), testing for *KRAS* mutations is increasingly common in clinical practice in order to better direct treatment of CRC ([@bib3]). Although the role of *KRAS-*mutation status as a predictive biomarker for response to anti-EGFR-targeted therapy is well supported, the role of *KRAS* as a prognostic biomarker for CRC survival, independent of anti-EGFR therapy, is less clear.

A number of previous studies have evaluated the relationship between *KRAS-*mutation status and survival after CRC diagnosis ([@bib5]; [@bib34]; [@bib6]; [@bib16]; [@bib38]; [@bib22]; [@bib29]; [@bib26]; [@bib33]; [@bib14]; [@bib18]; [@bib20]). In the largest study to date, [@bib6] reported that the presence of a somatic *KRAS* mutation was associated with statistically significantly poorer disease-free and overall survival after CRC diagnosis, but only among patients with Dukes\' C CRC and only among those with the *KRAS* p.G12V mutation ([@bib6]). This latter finding was supported by results from a recent study in which *KRAS* codon 12 mutations, particularly the p.G12V mutation, but not *KRAS* codon 13 mutations were associated with poorer survival ([@bib20]). Thus, observed inconsistencies in the literature regarding the association between *KRAS-*mutation status and CRC survival may be related to differences in the distribution of specific *KRAS* mutations, stage at diagnosis, or other characteristics.

Correlations between *KRAS-*mutation status and other tumour characteristics of prognostic relevance may further complicate the study of this marker in relation to prognosis. In particular, *KRAS*-mutated CRC is less likely to exhibit microsatellite instability (MSI) than *KRAS-*wild-type CRCs ([@bib29]; [@bib26]; [@bib33]; [@bib18]; [@bib20]) and is almost never *BRAF*-mutated ([@bib22]; [@bib14]; [@bib18]; [@bib20]). The presence of high MSI (MSI-H) is associated with a more favourable prognosis ([@bib17]), whereas *BRAF*-mutated CRC has a poorer prognosis than *BRAF*-wild-type disease ([@bib30]; [@bib33]; [@bib14]). Failure to account for these attributes of *KRAS*-mutated CRC could thus obscure an association between *KRAS-*mutation status and CRC survival.

To better understand the relationship between *KRAS-*mutation status and survival after CRC diagnosis, we used data from two concurrent population-based studies of incident invasive CRC conducted in Western Washington State.

Materials and Methods
=====================

Study population
----------------

Details of the population-based study samples have been published elsewhere ([@bib27], [@bib28]). Briefly, eligible participants included men and women diagnosed with invasive CRC between January 1998 and June 2002 who, at the time of diagnosis, were aged 20--74 years and resided in King, Pierce, or Snohomish counties in Western Washington State. Women who resided in 10 additional Washington counties and were diagnosed during the same time period at ages 50--74 years were also eligible. During a second phase of study recruitment, we identified eligible participants as men and women with invasive CRC in this 13-county ascertainment area who were diagnosed at ages 18--49 years between April 2002 and July 2007. All cases were identified through the Surveillance, Epidemiology, and End Results (SEER) cancer registry serving Western Washington State. Study eligibility was limited to English speakers with a publicly available telephone number. Of 3585 individuals contacted and identified as eligible, 463 (13%) were deceased, 351 (10%) refused participation, 128 (4%) could not be reached, and 24 (0.7%) completed only a partial interview. In total, 76% of eligible cases were enrolled in the study (*N*=2708).

At an average of 8.6 months after diagnosis, participants completed a structured telephone interview in which they were asked to provide detailed information on a number of potential risk factors, including smoking history, body mass index (BMI), family history of CRC, and use of selected medications. At the conclusion of the interview, participants were asked for consent to access diagnostic tumour specimens. Adequate tumour specimens were obtained for 78% of enrolled participants (*N*=2120).

This study was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center in accordance with assurances filed with and approved by the US Department of Health and Human Services.

*KRAS-*mutation testing and additional tumour characterisation
--------------------------------------------------------------

DNA was extracted from paraffin-embedded formalin-fixed tumour tissue. In cases for whom tumour DNA was successfully extracted (*N*=1989), the coding sequence of *KRAS* exon 2 was amplified ([@bib31]). Mutations in exon 2 were identified via forward and reverse sequencing of amplified tumour DNA ([@bib4]). Cases for whom *KRAS* testing failed (*N*=36) or produced equivocal results (*N*=30) were classified as having unknown *KRAS-*mutation status. For quality control purposes, sequencing was also conducted on three cell-line controls (one containing the p.G12V mutation, one containing the p.G13D mutation, and one wild-type cell line).

Tumour specimens were also assayed for *BRAF-*mutation status and for the presence of MSI. Tumour DNA was tested for the c.1799 T\>A (p.V600E) *BRAF* mutation using a fluorescent allele-specific PCR assay as described previously ([@bib10]). With respect to MSI status, testing for cases enrolled in earlier years of recruitment (*N*=1430) was based on a 10-gene panel assayed in tumour DNA and in DNA extracted from normal surrounding tissue (BAT25, BAT26, BAT40, MYCL, D5S346, D17S250, ACTC, D18S55, D10S197, and BAT34C4) ([@bib8]; [@bib28]); tumours were classified as MSI-H if instability was observed in ⩾30% of markers, and as MSS if instability was observed in \<30% of markers. For more recently enrolled cases (*N*=470), MSI status was based on immunohistochemistry (IHC) testing of four markers: MLH1, MSH2, MSH6, and PMS2 ([@bib24]; [@bib35]); cases whose tumour tissue exhibited positive staining for all markers were considered MSS, whereas cases negative for at least one marker were considered MSI-H. High concordance between IHC and PCR-based MSI testing has been demonstrated elsewhere ([@bib12]). Cases for whom test results were equivocal or for whom testing was not completed (*N*=80) were classified as having unknown MSI status.

Information on tumour site and stage at diagnosis was available from SEER. Tumours located in the caecum through the splenic flexure were grouped together as proximal colon cancers (ICD-O-3 codes C180, C182, C183, C184, and C185) ([@bib39]). Tumours located in the descending (C186) and sigmoid colon (C187) were classified as distal colon cancer, and tumours in the rectosigmoid junction (C199) and rectum (C209) were grouped together as rectal cancer. Stage at diagnosis was recorded according to SEER summary staging conventions (localised-, regional-, distant-stage).

Survival information
--------------------

Vital status was determined via linkage to SEER and the National Death Index. For cases who died during study follow-up, information was obtained on the date and cause of death, classified according to ICD-10 conventions ([@bib40]). Deaths with an underlying cause attributed to ICD-10 codes C18.0-C20.0 or C26.0 (that is, CRC) were classified as disease-specific mortality events. Vital-status linkage was performed periodically, with the most recent linkage capturing deaths occurring through September 2010.

Statistical analysis
--------------------

We used Cox proportional hazards regression to evaluate the association between *KRAS-*mutation status and survival after CRC diagnosis. The time axis for analysis was defined as days since diagnosis, with left censoring of participants until the date of study enrollment. We conducted separate survival analyses for disease-specific survival and overall survival. In all analyses, participants still alive at their last vital-status assessment were censored at that date. In analyses of disease-specific survival, we also censored persons who died due to causes other than CRC at the time of death. We evaluated associations between *KRAS-*mutation status and survival outcomes in the full cohort and within strata defined by patient characteristics (age at diagnosis, sex) and tumour characteristics (tumour site, stage, MSI status). In light of the fact that somatic mutations in *KRAS* and *BRAF* rarely co-occur ([@bib13]), and given that *BRAF*-mutated CRC has been shown to have a poorer prognosis than *BRAF-*wild-type CRC ([@bib30]; [@bib33]; [@bib14]), we conducted separate analyses: (1) in all cases irrespective of *BRAF*-mutation status; (2) restricted to *BRAF*-wild-type cases; and (3) combining information on *KRAS* and *BRAF* mutations to evaluate relative differences in survival for cases with a mutation in either *vs* neither gene. We also evaluated relative differences in survival between case groups defined by joint *KRAS*/MSI status, and by joint *KRAS/BRAF/*MSI status. Finally, we explored associations between different classes of *KRAS* mutations and survival outcomes, examining associations with specific mutations evident in ⩾5% of cases, and, more generally, with codon 12 mutations and codon 13 mutations separately; differences in codon-specific associations were evaluated via tests for heterogeneity. For all analyses, proportional hazards assumptions were assessed by testing for a non-zero slope of the scaled Schoenfeld residuals on ranked failure times ([@bib37]).

Regression models included adjustment terms for age (5-year categories), sex, and study phase. We also assessed potential confounding by several patient and tumour characteristics: cigarette smoking (never, former, current); BMI 2 years before diagnosis (\<25.0, 25.0--29.9, ⩾30.0 kg m^−2^); race (white, non-white); regular use of non-steroidal anti-inflammatory drugs at baseline (no, yes); family history of CRC in first-degree relatives (no, yes); and tumour site (proximal colon, distal colon/rectum). Of these additional factors, only cigarette smoking and BMI were retained in our final analytic model as adjustment for other variables had minimal impact on effect estimates (\<5% change).

We conducted sensitivity analyses using alternative approaches to assess the potential impact of excluding enrolled cases with unknown *KRAS-*mutation status. Specifically, we replicated analyses: (1) including all cases with missing *KRAS-*mutation status as *KRAS* wild-type; (2) including cases with missing *KRAS-*mutation status as *KRAS*-mutated; and (3) using multiple imputation for missing *KRAS* status. The multiple imputation model was based on all covariate variables from the multivariate model, as well as family history of CRC, tumour site, MSI status, *BRAF-*mutation status, race, survival time, and the survival outcome of interest ([@bib25]; [@bib36]). All analyses were conducted in STATA SE version 12.0 (College Park, TX, USA).

Results
=======

Characteristics of the study population are presented in [Table 1](#tbl1){ref-type="table"} by *KRAS-*mutation status. Approximately 31% of cases had *KRAS*-mutated CRC. Compared with cases with *KRAS-*wild-type CRC, cases with *KRAS*-mutated disease were statistically significantly less likely to have MSI-H or *BRAF*-mutated CRC (*P*-value\<0.001). There was no statistically significant difference in the distribution of age at diagnosis, sex, tumour site, or stage according to *KRAS-*mutation status. Overall, 38% (*N*=728) of cases died during the study follow-up period (mean=6.5 years, range=5.3 months to 13.7 years). Of those cases who died, ∼62% (*N*=449) died because of CRC.

Multivariate-adjusted analyses of disease-specific survival yielded estimates nearly identical to those from unadjusted analyses, and provided evidence of statistically significantly poorer survival in cases with *KRAS*-mutated *vs KRAS-*wild-type CRC ([Table 2](#tbl2){ref-type="table"}) (hazard ratio (HR)=1.37, 95% confidence interval (CI): 1.13--1.66). The magnitude of this association was similar when cases with *BRAF*-mutated disease were excluded or combined with the *KRAS*-mutated case group. Interaction terms by age at diagnosis, sex, tumour site, stage, and MSI status were not statistically significant (*P*\>0.05); however, point estimates did vary slightly by stage and age at diagnosis. In particular, *KRAS*-mutation status was not associated with survival in cases who presented with distant-stage disease (*P*-interaction by stage=0.07). Additionally, *KRAS*-mutated CRC was associated with statistically significantly poorer disease-specific survival in cases aged ⩾50 years at diagnosis but not in those aged \<50 (*P*-interaction by age=0.15). These non-significant differences in the strength of association across stage and age strata were diminished in analyses combining cases with *BRAF*-mutated and *KRAS*-mutated CRC. Associations were similar but attenuated in analyses of overall survival ([Table 3](#tbl3){ref-type="table"}).

In analyses considering *KRAS* in combination with MSI status ([Table 4](#tbl4){ref-type="table"}), disease-specific and overall survival were statistically significantly more favourable in cases with *KRAS*-wild-type/MSI-H CRC (HR=0.35, 95% CI: 0.23--0.55, and HR=0.78, 95% CI: 0.60--1.00, respectively) and statistically significantly poorer in cases with *KRAS*-mutated/MSS CRC (HR=1.24, 95% CI: 1.01--1.52, and HR=1.21, 95% CI: 1.02--1.43, respectively) compared with cases with *KRAS*-wild-type/MSS disease. Results were similar after excluding cases with *BRAF-*mutated CRC. Patterns of association also changed very little when combining cases with *KRAS*- and/or *BRAF*-mutated disease: cases with *KRAS*- and *BRAF*-wild-type/MSI-H disease had the most favourable prognosis, and those with *KRAS*- or *BRAF*-mutated/MSS disease had the poorest survival.

Among cases with *KRAS*-mutated CRC, 75% (*N*=444) had a mutation in codon 12 and 22% (*N*=132) in codon 13 ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Compared with cases with a codon 12 *KRAS* mutation, those with a codon 13 mutation were statistically significantly more likely to have CRC located in the proximal colon (54% *vs* 40%) and to have MSI-H disease (19% *vs* 7%). We found no statistically significant differences in the association between *KRAS-*mutation status and survival when we evaluated associations with mutated codon 12 *vs* mutated codon 13 (*P*-heterogeneity=0.54 and *P*-heterogeneity=0.30 for disease-specific and overall survival, respectively). The presence of a somatic p.G13D mutation was associated with statistically significantly poorer disease-specific (HR=1.48, 95% CI: 1.04--2.04) and overall survival (HR=1.38, 95% CI: 1.05--1.81) compared with *KRAS*-wild-type; neither p.G12D nor p.G12V mutations were significantly associated with survival outcomes when evaluated separately ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Compared with cases with known *KRAS-*mutation status, enrolled cases with unknown *KRAS* status were younger at diagnosis (median age=52 years *vs* 60 years), more likely to have distant-stage disease (20% *vs* 12%), and had a lower 5-year overall survival (65% *vs* 74%) (not shown). In sensitivity analyses, we evaluated the effect of missing information on *KRAS* status (*N*=728, 29%). In analyses based on our primary analytic model with no exclusion of *BRAF*-mutated cases, including all cases with unknown *KRAS-*mutation status as *KRAS*-mutated cases increased point estimates to HR=1.53 (95% CI: 1.13--1.79) for disease-specific survival and HR=1.39 (95% CI: 1.23--1.57) for overall survival. When we instead included these 728 cases as *KRAS*-wild-type, point estimates fell to HR=1.12 (95% CI: 0.94--1.34) and HR=1.06 (95% CI: 0.92--1.23) for disease-specific and overall survival, respectively. Thus, our point estimates comparing survival in *KRAS*-mutated *vs KRAS*-wild-type cases are subject to some uncertainty due to the exclusion of cases with missing *KRAS* data. However, when we implemented a multiple imputation model to account for missingness in *KRAS*, our results based on the analysis of known and imputed *KRAS* data indicated statistically significantly poorer disease-specific (HR=1.35, 95% CI: 1.12--1.63) and overall survival (HR=1.22, 95% CI: 1.05--1.42) associated with the presence of a *KRAS* mutation.

Discussion
==========

In this large population-based cohort of men and women with incident invasive CRC, the presence of a somatic *KRAS* mutation was associated with statistically significantly poorer survival, specifically in those without distant-stage disease. Patients with *KRAS*-mutated CRC, whose tumours were also MSS, had the poorest prognosis. These patterns of association were relatively unchanged when limited to *BRAF*-wild-type cases and when grouping *BRAF*-mutated and *KRAS*-mutated cases. Contrary to some previous reports, we did not find the association between *KRAS-*mutation status and survival to be limited to the p.G12V *KRAS*-mutation specific identified mutations.

Activating mutations in *KRAS* are among the most common mutations in human cancers ([@bib19]). Mutations in *KRAS* codons 12 and 13 have been shown to result in an altered RAS protein with greater resistance to GTPase activity ([@bib9]; [@bib1]). By remaining in an active GTP-bound state for longer, mutated RAS contributes to enhanced cellular growth and proliferation ([@bib1]), activating the RAS/RAF/MAPK and the phosphoinositide 3-kinase-AKT pathways. The relationship between constitutive activation of the RAS/RAF/MAPK signalling pathway and CRC prognosis has previously also been supported by studies evaluating the association between the *BRAF* p.V600E activating mutation and CRC survival ([@bib30]; [@bib33]; [@bib14]). Mutations in *BRAF* and *KRAS* are both thought to occur early in colorectal carcinogenesis, and are rarely observed together. Here, we found that only 1% (*N*=6) of CRC cases with a somatic *KRAS* mutation harboured a *BRAF* mutation, compared with 18% of *KRAS*-wild-type CRC cases; this is consistent with data from The Cancer Genome Atlas ([@bib11]) and recent reports from other large studies ([@bib18]; [@bib20]). When we combined information on *KRAS* and *BRAF* status to compare survival in CRC cases with a somatic mutation in at least one *vs* neither of these genes, we found only modest differences from our analyses where *BRAF*-mutation status was not considered.

The presence of a somatic *KRAS* mutation is also inversely associated with the presence of MSI ([@bib29]; [@bib26]; [@bib20]). MSI-H CRC is known to have a statistically significantly more favourable prognosis than MSS CRC ([@bib17]), and to have a distinct clinicopathology: the distribution of MSI follows a clear gradient of decreasing prevalence from the ascending colon to the rectum ([@bib41]) and is less prevalent in cases diagnosed at later stages ([@bib30]; [@bib26]). Although we found that the prevalence of MSI was statistically significantly lower in *KRAS*-mutated *vs KRAS*-wild-type cases, we found no difference in the distribution of tumour site or stage at diagnosis according to *KRAS* status. We also found no statistically significant interaction in the association between *KRAS-*mutation status and survival according to MSI status, tumour site, or stage at diagnosis. However, our results did suggest that *KRAS-*mutation status was not associated with survival in cases who presented with distant-stage disease, as has been suggested by at least two previous studies ([@bib26]; [@bib21]). Thus, although the prevalence of somatic *KRAS* mutations does not appear to differ by stage at diagnosis, the prognostic role of *KRAS* may differ by stage.

Several studies in the distant-stage, metastatic setting have demonstrated the utility of *KRAS-*mutation status as a predictive marker for response to anti-EGFR therapy ([@bib23]; [@bib7]). In a recent meta-analysis, [@bib23] reported that the presence of a *KRAS* mutation had a positive likelihood ratio of 2.0 (95% CI: 1.45--2.76) for predicting non-response to anti-EGFR in distant-stage CRC . However, the role of *KRAS* as a predictive marker has not been demonstrated for less advanced disease: recently published findings from a phase III randomized trial of patients with stage III colon cancer indicated no benefit in 3-year disease-free survival with the addition of cetuximab to standard chemotherapy, regardless of *KRAS-*mutation status (HR=1.21, 95% CI: 0.98--1.49 in *KRAS*-wild-type and HR=1.12, 95% CI: 0.86--1.46 in *KRAS* mutated) ([@bib2]). Results from that trial did, however, provide support for the role of *KRAS-*mutation status as a prognostic factor, independent of anti-EGFR therapy: 3-year disease-free survival ranged from 72--75% across treatment arms in participants with *KRAS*-wild-type disease *vs* 65--67% in participants with *KRAS*-mutated disease ([@bib2]).

Previous studies focused on *KRAS-*mutation status as a potential prognostic factor has been mixed in their findings. In the largest study of *KRAS-*mutation status and survival to date, the Kirsten Ras Colorectal Cancer Collaborative Group study (RASCAL, *N*=2721), [@bib5] reported statistically significantly poorer overall survival for *KRAS*-mutated *vs KRAS*-wild-type disease at a magnitude similar to that observed here (HR=1.22, 95% CI: 1.07--1.40). The majority of other, smaller studies have also indicated a poorer prognosis in patients with *KRAS*-mutated CRC ([@bib26]; [@bib14]; [@bib18]; [@bib20]). Several studies, however, have failed to find an association between *KRAS* and patient outcomes ([@bib34]; [@bib16]; [@bib38]; [@bib22]; [@bib29], [@bib30]; [@bib33]). The basis for these inconsistencies is unclear, but may be related to limited sample size and differences in the distribution and consideration of other factors, such as age at diagnosis, stage, and MSI status.

Prior studies have also differed in their consideration of specific *KRAS* mutations in relation to CRC survival. In an update of the original RASCAL study (RASCAL II, *N*=4268), [@bib6] found the association between *KRAS-*mutation status and survival was largely confined to the p.G12V mutation. [@bib20] recently reported a similar finding, and found that mutations in *KRAS* codon 13 were not associated with CRC survival. Unlike these reports, we did not find a statistically significant association between the p.G12V *KRAS* mutation and prognosis. Although experimental evidence has suggested that mutations in *KRAS* codon 12, particularly p.G12V, confer lower GTPase activity ([@bib9]; [@bib1]), which may translate to greater transforming potential, our data are not consistent with a clear difference in the prognostic significance of somatic *KRAS* mutations by codon.

Results presented here should be interpreted in the context of study limitations. Only limited information on first course of treatment was available and it is possible that treatment could have differed according to *KRAS-*mutation status; however, 95% of cases were diagnosed before 2006 at a time before *KRAS-*mutation status might have been used to decide on anti-EGFR therapy. *KRAS-*mutation status does not appear to be associated with differential response to other chemotherapies ([@bib32]; [@bib29]; [@bib18]). In addition, *KRAS-*mutation status was not determined for 29% of enrolled cases. Although these cases differed from cases with known *KRAS-*mutation status on several factors that could be related to prognosis, we obtained point estimates similar to those in our primary analyses in sensitivity analyses using multiple imputation to account for these missing data. *KRAS-*mutation status also could not be determined in cases who were not enrolled in the present study because of refusal, death before enrollment, or loss to follow-up. If *KRAS*-mutated CRC is truly associated with poorer prognosis, the prevalence of *KRAS* mutations is likely to have been higher in those cases who died before they could be enrolled in the study: exclusion of deceased cases would thus have attenuated, rather than inflated our estimates of the strength of association.

Important strengths of the present study include the population-based design and large sample size. Our consideration of both MSI and *BRAF-*mutation status in evaluating the relationship between *KRAS-*mutation status and CRC survival also represents an important strength. Here, we confirm previous reports that *KRAS*-mutated CRC is less likely to be MSI-H and is very rarely *BRAF* mutated. When we evaluated these three markers in combination in relation to survival, we found a strong gradient in risk, particularly with respect to disease-specific survival. Those individuals with CRC that was *KRAS*-wild-type, *BRAF*-wild-type, and MSI-H had the most favourable disease-specific survival; individuals with CRC that was *KRAS*- or *BRAF*-mutated and MSS experienced a statistically significantly poorer prognosis than other case groups defined by combinations of these three markers. These results support the prognostic significance of *KRAS-*mutation status beyond its now established role as a predictive marker in distant-stage CRC.
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###### Study population characteristics by *KRAS-*mutation status

                                                          ***KRAS*** **wild-type (*****N*****=1330)**   ***KRAS*****-mutated (*****N*****=593)**    ***P*****-value\***
  ------------------------------------------------------- --------------------------------------------- ------------------------------------------ ---------------------
  **Age at diagnosis**                                                                                                                             
  \<50                                                    346 (26)                                      147 (25)                                           0.65
  50--59                                                  291 (22)                                      143 (24)                                              
  60--69                                                  415 (31)                                      188 (32)                                              
  70--74                                                  278 (21)                                      115 (19)                                              
  **Sex**                                                                                                                                          
  Male                                                    609 (46)                                      264 (45)                                           0.61
  Female                                                  721 (54)                                      329 (55)                                              
  **Tumour site**                                                                                                                                  
  Proximal colon                                          505 (39)                                      255 (44)                                           0.10
  Distal colon                                            364 (28)                                      147 (25)                                              
  Rectal                                                  424 (33)                                      183 (31)                                              
  Unknown                                                 37                                            89                                                    
  **Stage at diagnosis[a](#t1-fn1){ref-type="fn"}**                                                                                                
  Localised                                               553 (42)                                      220 (37)                                           0.12
  Regional                                                610 (46)                                      293 (50)                                              
  Distant                                                 144 (11)                                      75 (13)                                               
  Unknown                                                 23                                            5                                                     
  **MSI status[a](#t1-fn1){ref-type="fn"}**                                                                                                        
  MSS/MSI-L                                               1042 (82)                                     509 (90)                                          \<0.001
  MSI-H                                                   236 (18)                                      56 (10)                                               
  Unknown                                                 52                                            28                                                    
  ***BRAF* mutation status[a](#t1-fn1){ref-type="fn"}**                                                                                            
  Wild-type                                               1083 (82)                                     580 (99)                                          \<0.001
  Mutated                                                 232 (18)                                      6 (1)                                                 
  Unknown                                                 15                                            7                                                     
  **Vital status**                                                                                                                                 
  Alive                                                   843 (63)                                      352 (59)                                           0.09
  Deceased                                                487 (37)                                      241 (41)                                              
  Mean years of follow-up (s.d.)                          6.7 (3.9)                                     6.3 (4.1)                                             

Abbreviations: KRAS=Kirsten Ras; MSI=microsatellite instability; MSI-H=high microsatellite instability.

\**P*-value for *χ*^2^.

\% distribution excludes cases with unknown value of characteristic.

###### *KRAS-*mutation status and disease-specific survival after colorectal cancer diagnosis by patient and tumour characteristics, with and without consideration of *BRAF-*mutation status

                              **All cases**   ***BRAF*****-wild-type CRC only**   **Joint** ***KRAS/BRAF*** **mutation status**                                                                 
  --------------------------- --------------- ----------------------------------- ----------------------------------------------- ---------- --------- ------------------- ---------- --------- -------------------
  Overall (unadjusted)        287/1330        162/593                             1.36 (1.12--1.65)                               238/1098   161/587   1.39 (1.14--1.70)   234/1083   214/834   1.31 (1.09--1.58)
  Overall (adjusted)          287/1330        162/593                             1.37 (1.13--1.66)                               238/1098   161/587   1.40 (1.14--1.72)   234/1083   214/834   1.34 (1.11--1.63)
  **By age at diagnosis**                                                                                                                                                                       
  \<50 years                  79/346          34/147                              1.03 (0.69--1.54)                               67/320     34/147    1.14 (0.76--1.73)   65/317     48/176    1.40 (0.96--2.03)
  ⩾50 years                   208/984         128/446                             1.48 (1.18--1.85)                               171/778    127/440   1.49 (1.18--1.88)   169/766    166/658   1.33 (1.07--1.66)
  **By sex**                                                                                                                                                                                    
  Male                        134/609         74/264                              1.35 (1.02--1.79)                               119/545    73/261    1.37 (1.03--1.85)   118/542    89/329    1.36 (1.03--1.79)
  Female                      153/721         88/329                              1.38 (1.06--1.81)                               119/553    88/326    1.43 (1.07--1.89)   116/541    125/505   1.35 (1.04--1.75)
  **By tumour site**                                                                                                                                                                            
  Proximal                    104/505         72/255                              1.44 (1.06--1.95)                               68/322     71/252    1.45 (1.04--2.04)   67/315     109/444   1.25 (0.92--1.71)
  Distal/rectal               178/788         87/330                              1.29 (1.00--1.68)                               166/745    87/327    1.33 (1.02--1.73)   163/737    101/376   1.35 (1.04--1.73)
  **By stage at diagnosis**                                                                                                                                                                     
  Localised                   29/553          19/220                              1.55 (0.85--2.82)                               28/463     19/216    1.38 (0.75--2.54)   28/458     20/311    1.06 (0.58--1.93)
  Regional                    146/610         83/293                              1.35 (1.03--1.78)                               111/487    82/291    1.47 (1.10--1.96)   109/480    121/424   1.50 (1.15--1.96)
  Distant                     111/144         59/75                               1.02 (0.73--1.41)                               98/129     59/75     1.06 (0.76--1.49)   96/126     72/90     1.11 (0.80--1.53)
  **By MSI**                                                                                                                                                                                    
  MSS                         257/1042        143/509                             1.24 (1.00--1.52)                               221/943    142/504   1.33 (1.07--1.65)   217/933    180/613   1.40 (1.15--1.72)
  MSI-H                       22/236          11/56                               2.06 (0.93--4.52)                               10/115     11/55     2.17 (0.89--5.31)   10/112     25/181    1.67 (0.77--3.61)

Abbreviations: CI=confidence interval; CRC=colorectal cancer; HR=hazard ratio; KRAS=Kirsten Ras; MSI=microsatellite instability; MSI-H=high microsatellite instability.

All associations are relative to the *KRAS* wild-type case group. All *P*-values for tests of interaction across strata indicate a lack of statistically significant interaction (*P*\>0.05).

Adjusted for age at diagnosis, sex, study population, body mass index, and history of cigarette smoking.

###### *KRAS-*mutation status and overall survival after colorectal cancer diagnosis by patient and tumour characteristics, with and without consideration of *BRAF-*mutation status

                              **All cases**   ***BRAF*****-wild-type CRC only**   **Joint** ***KRAS/ BRAF*** **mutation status**                                                                 
  --------------------------- --------------- ----------------------------------- ------------------------------------------------ ---------- --------- ------------------- ---------- --------- -------------------
  Overall (unadjusted)        487/1330        241/593                             1.22 (1.05--1.43)                                391/1098   239/587   1.28 (1.09--1.51)   386/1083   341/834   1.27 (1.10--1.47)
  Overall (adjusted)          487/1330        241/593                             1.24 (1.06--1.45)                                391/1098   239/587   1.27 (1.08--1.50)   386/1083   341/834   1.24 (1.07--1.44)
  **By age at diagnosis**                                                                                                                                                                        
  \<50 years                  98/346          41/147                              1.00 (0.70--1.45)                                86/320     41/147    1.07 (0.74--1.55)   84/317     55/176    1.22 (0.87--1.72)
  ⩾50 years                   389/984         200/446                             1.31 (1.10--1.56)                                305/778    198/440   1.33 (1.11--1.60)   293/766    286/658   1.24 (1.05--1.47)
  **By sex**                                                                                                                                                                                     
  Male                        238/609         115/264                             1.20 (0.96--1.50)                                207/545    114/261   1.24 (0.98--1.56)   205/542    146/329   1.25 (1.00--1.55)
  Female                      249/721         126/329                             1.30 (1.04--1.61)                                184/553    125/326   1.32 (1.05--1.67)   181/541    195/505   1.25 (1.01--1.53)
  **By tumour site**                                                                                                                                                                             
  Proximal                    195/505         109/255                             1.21 (0.95--1.54)                                121/322    107/252   1.24 (0.95--1.62)   120/315    185/444   1.13 (0.90--1.43)
  Distal/rectal               276/788         128/330                             1.22 (0.99--1.51)                                258/745    128/327   1.23 (0.99--1.53)   254/737    148/376   1.21 (0.99--1.49)
  **By stage at diagnosis**                                                                                                                                                                      
  Localised                   130/553         60/220                              1.19 (0.87--1.63)                                107/463    59/216    1.15 (0.83--1.59)   106/458    83/311    1.05 (0.78--1.42)
  Regional                    227/610         117/293                             1.24 (0.99--1.55)                                171/487    116/291   1.33 (1.05--1.69)   169/480    177/424   1.36 (1.09--1.68)
  Distant                     118/144         62/75                               1.01 (0.73--1.38)                                104/129    62/75     1.05 (0.75--1.45)   102/126    76/90     1.09 (0.80--1.49)
  **By MSI**                                                                                                                                                                                     
  MSS                         391/1042        213/509                             1.21 (1.02--1.43)                                344/943    212/504   1.26 (1.06--1.51)   340/933    261/613   1.28 (1.09--1.51)
  MSI-H                       79/236          17/56                               1.20 (0.68--2.12)                                32/115     16/55     1.20 (0.63--2.30)   32/112     67/181    1.05 (0.67--1.64)

Abbreviations: CI=confidence interval; CRC=colorectal cancer; HR=hazard ratio; KRAS=Kirsten Ras; MSI=microsatellite instability; MSI-H=high microsatellite instability; mut=mutated; wt=wild-type.

All associations are relative to the *KRAS* wild-type case group. All *P*-values for tests of interaction across strata indicate a lack of statistically significant interaction (*P*\>0.05).

Adjusted for age at diagnosis, sex, study population, body mass index, and history of cigarette smoking.

###### *KRAS-*mutation status, in combination with MSI and *BRAF*-mutation status, in relation to disease-specific and overall survival after colorectal cancer diagnosis

                                                             **Disease-specific survival**   **Overall survival**             
  --------------------------------------------------------- ------------------------------- ---------------------- ---------- -------------------
  **Joint *KRAS* and MSI status**                                                                                             
  KRAS wt/MSI-H                                                         22/236                0.35 (0.23--0.55)      79/236    0.78 (0.60--1.00)
  KRAS mut/MSI-H                                                         11/56                0.77 (0.42--1.41)      17/56     0.87 (0.53--1.42)
  KRAS wt/MSS                                                          257/1042                   1.00 (ref)        391/1042      1.00 (ref)
  KRAS mut/MSS                                                          143/509               1.24 (1.01--1.52)     213/509    1.21 (1.02--1.43)
  **Joint *KRAS* and MSI status (*BRAF* wild-type only)**                                                                     
  KRAS wt/MSI-H                                                         10/112                0.34 (0.18--0.65)      32/112    0.74 (0.51--1.07)
  KRAS mut/MSI-H                                                         11/53                0.87 (0.47--1.60)      16/53     0.92 (0.55--1.52)
  KRAS wt/MSS                                                           217/933                   1.00 (ref)        340/933       1.00 (ref)
  KRAS mut/MSS                                                          141/501               1.36 (1.09--1.68)     210/501    1.27 (1.07--1.52)
  **Joint *KRAS*, *BRAF*, and MSI status**                                                                                    
  KRAS and BRAF wt/MSI-H                                                10/112                0.34 (0.18--0.65)      32/112    0.75 (0.52--1.08)
  KRAS or BRAF mut/MSI-H                                                25/181                0.60 (0.39--0.91)      67/181    0.91 (0.69--1.20)
  KRAS and BRAF wt/MSS                                                  217/933                   1.00 (ref)        340/933       1.00 (ref)
  KRAS or BRAF mut/MSS                                                  180/613               1.41 (1.15--1.73)     261/613    1.28 (1.08--1.51)

Abbreviations: CI=confidence interval; HR=hazard ratio; KRAS=Kirsten Ras; MSI=microsatellite instability; MSI-H=high microsatellite instability; mut=mutated; wt=wild-type.

Adjusted for age at diagnosis, sex, study population, body mass index, and history of cigarette smoking.
